The company was chosen alongside 12 high potential health startups that feature a broad range of cutting-edge technologies in the therapeutic, medical device, and digital health space
Flosonics Medical is pleased to announce that it was accepted into the Ontario Bioscience Organization’s 2016 Capital Access Advisory Program (CAAP).
The Canadian medical device company was chosen alongside 12 high-potential health startup companies that feature a broad range of cutting-edge technologies in the therapeutic, medical device, and digital health space.
CAAP is a collaborative initiative that harnesses the expertise and engagement of the Ontario health science community and life science investors and entrepreneurs across Canada and the U.S. The program aims to accelerate the growth of this important sector in Ontario.
Flosonics Medical is the developer of FloPatch, the world’s first wireless, wearable Doppler ultrasound system that enables rapid, repeatable, and trusted hemodynamic assessments throughout the continuum of care.
“Our management team is excited to participate in the CAAP program. We feel the mentorship provided by OBIO’s team will help crystallize the value proposition of our innovative technology,” said Joe Eibl, co-founder and CEO of Flosonics Medical.
OBIO launched the 2016 Capital Access Advisory Program with an event hosted at Norton Rose Fulbright in Toronto on April 13 where the 12 program participants had the chance to connect and introduce their technologies.
The participants were also given the opportunity to learn about OBIO’s CAAP program and meet with steering committee members.
The 2016 CAAP participants were selected for their high-impact technologies such as a smart contact lens for monitoring blood glucose, a wound monitoring smartphone application, and medical device and drug therapeutics for epilepsy.
“CAAP is a focused opportunity for early-stage bioscience companies to gain access to investors, advisors, and mentorship. CAAP allows companies to rapidly execute on their strategic business goals, accelerate business development and attract necessary financing for growth,” said Gail Garland, president and CEO of OBIO.
The Ontario Bioscience Innovation Organization (OBIO) is a not-for-profit, membership-based organization engaged in the development of an integrated health innovation economy for Ontario and one that will become a global leader in providing health technology products and services to the international marketplace. OBIO advances this goal through advocacy, promotion and strategic leadership and via collaborative partnerships with industry, academia, patients and government. For more information please visit www.obio.ca and follow OBIO on Twitter @OBIOscience.